Clobutinol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 16:55, 8 December 2020 (Task 18 (cosmetic): eval 4 templates: del empty params (1×);). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Clobutinol
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration
oral
ATC code
Legal status
Legal status
  • Withdrawn
(EU)
Identifiers
  • (RS)-1-(4-chlorophenyl)-4-dimethylamino-2,3-dimethyl-butan-2-ol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.035.373 Edit this at Wikidata
Chemical and physical data
FormulaC14H22ClNO
Molar mass255.79 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • Clc1ccc(cc1)CC(O)(C)C(C)CN(C)C
  • InChI=1S/C14H22ClNO/c1-11(10-16(3)4)14(2,17)9-12-5-7-13(15)8-6-12/h5-8,11,17H,9-10H2,1-4H3 checkY
  • Key:KVHHQGIIZCJATJ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Clobutinol is a cough suppressant distributed by Boehringer Ingelheim, Novartis's Hexal (Sandoz), Stada and possibly other companies.

Side effects and withdrawal

Studies in 2004 had indicated that clobutinol has the potential to prolong the QT interval.[1] Clobutinol was in 2007 determined to cause cardiac arrhythmia in some patients.[2]

Boehringer Ingelheim products containing clobutinol were voluntarily withdrawn from sale in Germany, and the rest of the world, on August 31, 2007.[3]

The approval for Germany and the EU was revoked in 2008.[4]

See also

References

  1. ^ Bellocq C, Wilders R, Schott JJ, Louérat-Oriou B, Boisseau P, Le Marec H, et al. (November 2004). "A common antitussive drug, clobutinol, precipitates the long QT syndrome 2". Molecular Pharmacology. 66 (5): 1093–102. doi:10.1124/mol.104.001065. PMID 15280442.
  2. ^ "Clobutinol-haltige Arzneimittel: BfArM ordnet Widerruf der Zulassung an". BfArM (German Federal Institute for Drugs and Medical Devices). 2007-08-31. Archived from the original on 2012-04-01. Clobutinol: BfArM orders cancellation of approval
  3. ^ "Boehringer Ingelheim voluntarily withdraws its clobutinol containing medications". Boehringer Ingelheim. 2007-08-31. Archived from the original on 2012-01-27.
  4. ^ "Cancellation of approval" (PDF). BfArM (German Federal Institute for Drugs and Medical Devices). 2008-06-06. Archived from the original (pdf) on 2012-04-01. Die Zulassungen für die o.g. Arzneimittel werden mit sofortiger Wirkung widerrufen.